<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109405">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02090764</url>
  </required_header>
  <id_info>
    <org_study_id>P-110881-01</org_study_id>
    <nct_id>NCT02090764</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo</brief_title>
  <official_title>A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferrer Internacional S.A.</source>
  <oversight_info>
    <authority>United States and Puerto Rico: Food and Drug Administration</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Germany: The Bavarian State Ministry of the Environment and Public Health</authority>
    <authority>Romania: Ministry of Public Health</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Russia: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority
      clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical
      diagnosis of non-bullous or bullous impetigo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>Visit 3 (Day 6-7)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <condition>Impetigo</condition>
  <arm_group>
    <arm_group_label>Ozenoxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozenoxacin</intervention_name>
    <arm_group_label>Ozenoxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of bullous or non bullous impetigo. The patient has a total
             affected area comprised between 1-100 cm2 with surrounding erythema not extending
             more than 2 cm from the edge of any affected area. In case of multiple affected areas
             the total area will be the sum of each affected area and will not exceed 100 cm2.
             Additionally for patients &lt; 12 years the total area will not exceed a maximum of 2%
             of the body surface area.

          -  Total Skin Infection Rating Scale (SIRS) score of at least 3, including pus/exudate
             score of at least 1

        Exclusion Criteria:

          -  Has a bacterial infection, which in the opinion of the investigator, could not be
             appropriately treated by a topical antibiotic.

          -  Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary
             temperature over 37.2 °C (99.0 °F)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Impetigo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
